Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y663

UPID:
HS3SA_HUMAN

ALTERNATIVE NAMES:
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1

ALTERNATIVE UPACC:
Q9Y663; A8K7N2

BACKGROUND:
The enzyme Heparan sulfate glucosamine 3-O-sulfotransferase 3A1, also known as Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1, is pivotal in the sulfation process of heparan sulfate. This process is essential for the creation of specific binding sites for Herpes simplex virus-1 on heparan sulfate, facilitating viral entry into host cells. The enzyme's activity does not, however, convert heparan sulfate into its anticoagulant form, indicating a selective role in cellular interactions and viral infection mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 offers a promising avenue for developing antiviral therapies. By inhibiting this enzyme, it might be possible to block the initial step of Herpes simplex virus-1 infection, providing a targeted strategy to combat this common viral pathogen.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.